Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jemperli
Pharma
GSK trial result mirrors Merck's problem in ovarian cancer
Merck's and GSK's similar overall survival setbacks suggest that PD-1 inhibitors may not be for ovarian cancer after all.
Angus Liu
Dec 20, 2024 10:46am
GSK blows Jemperli marching brass against Keytruda with new nod
Aug 1, 2024 3:00pm
Merck's Keytruda misses the mark in endometrial cancer study
May 9, 2024 10:55am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
GSK tees up AstraZeneca rivalry with Jemperli-Zejula combo data
Dec 18, 2023 11:13am
In industry first, GSK's PD-1 trial hits overall survival goal
Oct 30, 2023 2:00am
